MorphoSys AG
WKN: 663200 | ISIN: DE0006632003 | FSE: MOR | NASDAQ: MOR
MorphoSys AG (FSE & NASDAQ: MOR) is a global commercial-stage biopharmaceutical company. MorphoSys uses groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients. MorphoSys markets its proprietary medicine Monjuvi® (tafasitamab-cxix) in the United States – a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a potential first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a selective small-molecule BET inhibitor, is studied as a potential treatment for myelofibrosis – a type of bone marrow cancer for which treatment options are limited; and tulmimetostat, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, please visit www.morphosys.com